NEW YORK (GenomeWeb News) – Proteome Sciences will supply its tandem mass tag — or TMT — technology to German drug discovery company Cellzome, Proteome Sciences announced today.
 
Cellzome was an early beta test site for Proteome Sciences’ TMTsixplex, which allows up to six samples to be labeled, mixed, and subsequently identified. Now, Cellzome plans to apply the TMTsixplex technology to its own proteomics platform approach for analyzing protein-drug and protein-protein interactions.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.